BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lamarca A, Edeline J, McNamara MG, Hubner RA, Nagino M, Bridgewater J, Primrose J, Valle JW. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat Rev. 2020;84:101936. [PMID: 31986437 DOI: 10.1016/j.ctrv.2019.101936] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Yu Y, Huang S, Chen J, Yu F, Zhang L, Xiang X, Deng J, Fang Z, Li J, Xiong J. An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers. Cancer Control 2021;28:10732748211017165. [PMID: 33982628 DOI: 10.1177/10732748211017165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zheng Q, Zhang B, Li C, Zhang X. Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models. Front Oncol 2022;12:850732. [PMID: 35372014 DOI: 10.3389/fonc.2022.850732] [Reference Citation Analysis]
3 Lamarca A, Santos-Laso A, Utpatel K, La Casta A, Stock S, Forner A, Adeva J, Folseraas T, Fabris L, Macias RIR, Krawczyk M, Krawczyk M, Cardinale V, Braconi C, Alvaro D, Evert M, Banales JM, Valle JW; Group: on behalf of the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. Hepatology 2021;73:2311-25. [PMID: 33073396 DOI: 10.1002/hep.31598] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
4 Marcus R, Ferri-Borgogno S, Hosein A, Foo WC, Ghosh B, Zhao J, Rajapakshe K, Brugarolas J, Maitra A, Gupta S. Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:5709. [PMID: 34830866 DOI: 10.3390/cancers13225709] [Reference Citation Analysis]
5 Zhang X, Kong Z, Xu X, Yun X, Chao J, Ding D, Li T, Gao Y, Guan N, Zhu C, Qin X. ARRB1 Drives Gallbladder Cancer Progression by Facilitating TAK1/MAPK Signaling Activation. J Cancer 2021;12:1926-35. [PMID: 33753990 DOI: 10.7150/jca.53325] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Song S, Yang W, Tian H, Gong S, Lei C, Lv K, Lu T, Cheng Q, Yang K, Guo T. The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2021;:101788. [PMID: 34389530 DOI: 10.1016/j.clinre.2021.101788] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kaneko S, Kurosaki M, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Itakura J, Takahashi Y, Nakanishi H, Asano D, Irie T, Kawachi Y, Izumi N. Prognosis of intrahepatic cholangiocarcinoma stratified by albumin-bilirubin grade. Hepatol Res 2021;51:902-8. [PMID: 34046984 DOI: 10.1111/hepr.13673] [Reference Citation Analysis]
8 Messori A, Bartoli L, Trippoli S. Adjuvant treatments in biliary tract cancer: an analysis based on restricted mean survival time. Digestive and Liver Disease 2020;52:1208-9. [DOI: 10.1016/j.dld.2020.05.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Louis C, Edeline J, Coulouarn C. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opin Ther Targets 2021;25:153-62. [PMID: 33502260 DOI: 10.1080/14728222.2021.1882998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Xu S, Zhang XP, Zhao GD, Zhao ZM, Gao YX, Hu MG, Tan XL, Liu R. Development and validation of an online calculator to predict early recurrence and long-term survival in patients with distal cholangiocarcinoma after pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci 2021. [PMID: 34676993 DOI: 10.1002/jhbp.1058] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Meng Z, Xue H, Wang T, Chen B, Dong X, Yang L, Dai J, Lou X, Xia F. Aggregation-induced emission photosensitizer-based photodynamic therapy in cancer: from chemical to clinical. J Nanobiotechnology 2022;20:344. [PMID: 35883086 DOI: 10.1186/s12951-022-01553-z] [Reference Citation Analysis]
12 Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. Cancer Treat Res Commun 2021;27:100354. [PMID: 33756174 DOI: 10.1016/j.ctarc.2021.100354] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557-588. [PMID: 32606456 DOI: 10.1038/s41575-020-0310-z] [Cited by in Crossref: 456] [Cited by in F6Publishing: 370] [Article Influence: 228.0] [Reference Citation Analysis]
14 Wang N, Huang A, Kuang B, Xiao Y, Xiao Y, Ma H. Progress in Radiotherapy for Cholangiocarcinoma. Front Oncol 2022;12:868034. [DOI: 10.3389/fonc.2022.868034] [Reference Citation Analysis]
15 Li D, Zhang YH, Crook CJ, Iyer RV. Updates in Biliary Tract Cancers. Cancers (Basel) 2022;14:2746. [PMID: 35681726 DOI: 10.3390/cancers14112746] [Reference Citation Analysis]
16 de Souza GMV, Ribeiro IB, Funari MP, de Moura DTH, Scatimburgo MVCV, de Freitas Júnior JR, Sánchez-Luna SA, Baracat R, de Moura ETH, Bernardo WM, de Moura EGH. Endoscopic retrograde cholangiopancreatography drainage for palliation of malignant hilar biliary obstruction — stent-in-stent or side-by-side? A systematic review and meta-analysis. World J Hepatol 2021; 13(5): 595-610 [PMID: 34131473 DOI: 10.4254/wjh.v13.i5.595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Gutiérrez-Larrañaga M, González-López E, Roa-Bautista A, Rodrigues PM, Díaz-González Á, Banales JM, López-Hoyos M, Santos-Laso A, Crespo J. Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy? Liver Cancer 2021;10:545-60. [PMID: 34950178 DOI: 10.1159/000518104] [Reference Citation Analysis]
18 Primrose JN. Adjuvant Chemotherapy in Resected Biliary Tract Cancer. Ann Surg Oncol 2020;27:2127-9. [PMID: 32378086 DOI: 10.1245/s10434-020-08537-z] [Reference Citation Analysis]
19 Rizzo A, Ricci AD, Brandi G. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? Cancer Treat Res Commun 2021;27:100356. [PMID: 33799004 DOI: 10.1016/j.ctarc.2021.100356] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Marin JJG, Sanchon-Sanchez P, Cives-Losada C, Del Carmen S, González-Santiago JM, Monte MJ, Macias RIR. Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. Cancers (Basel) 2021;13:2358. [PMID: 34068398 DOI: 10.3390/cancers13102358] [Reference Citation Analysis]
21 Kuipers H, Hoogwater FJ, Holtman GA, van der Hoorn A, de Boer MT, de Haas RJ. Clinical value of diffusion-weighted MRI for differentiation between benign and malignant gallbladder disease: a systematic review and meta-analysis. Acta Radiol 2021;62:987-96. [PMID: 32830511 DOI: 10.1177/0284185120950115] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
22 Marin JJG, Prete MG, Lamarca A, Tavolari S, Landa-Magdalena A, Brandi G, Segatto O, Vogel A, Macias RIR, Rodrigues PM, Casta A, Mertens J, Rodrigues CMP, Fernandez-Barrena MG, Da Silva Ruivo A, Marzioni M, Mentrasti G, Acedo P, Munoz-Garrido P, Cardinale V, Banales JM, Valle JW, Bridgewater J, Braconi C; working group 6 of the COST-action 18122 (Euro-Cholangio-NET) as part of the European Network for the study of Cholangiocarcinoma (ENSCCA). Current and novel therapeutic opportunities for systemic therapy in biliary cancer. Br J Cancer 2020;123:1047-59. [PMID: 32694694 DOI: 10.1038/s41416-020-0987-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
23 D’amico FE, Mescoli C, Caregari S, Pasquale A, Billato I, Alessandris R, Lanari J, Bassi D, Boetto R, D’amico F, Vitale A, Lonardi S, Gringeri E, Cillo U. Impact of Positive Radial Margin on Recurrence and Survival in Perihilar Cholangiocarcinoma. Cancers 2022;14:1680. [DOI: 10.3390/cancers14071680] [Reference Citation Analysis]
24 Gkika E, Hawkins MA, Grosu AL, Brunner TB. The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer. Front Oncol 2020;10:604387. [PMID: 33381458 DOI: 10.3389/fonc.2020.604387] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Lamarca A, Edeline J, Goyal L. How I treat biliary tract cancer. ESMO Open 2022;7:100378. [PMID: 35032765 DOI: 10.1016/j.esmoop.2021.100378] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 van Keulen AM, Buettner S, Besselink MG, Busch OR, van Gulik TM, Ijzermans JNM, de Jonge J, Polak WG, Swijnenburg RJ, Groot Koerkamp B, Erdmann JI, Olthof PB. Surgical morbidity in the first year after resection for perihilar cholangiocarcinoma. HPB (Oxford) 2021:S1365-182X(21)00098-8. [PMID: 33947606 DOI: 10.1016/j.hpb.2021.03.016] [Reference Citation Analysis]
27 Rizzo A, Brandi G. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. Expert Review of Gastroenterology & Hepatology 2021;15:483-5. [DOI: 10.1080/17474124.2021.1864325] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
28 Rizzo A, Brandi G. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. Expert Review of Gastroenterology & Hepatology 2021;15:547-54. [DOI: 10.1080/17474124.2021.1890031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
29 Xu S, Zhang XP, Zhao GD, Zou WB, Zhao ZM, Hu MG, Gao YX, Tan XL, Liu Q, Liu R. A novel online calculator to predict recurrence risk in patients with distal cholangiocarcinoma after radical pancreaticoduodenectomy. J Surg Oncol 2021. [PMID: 34617593 DOI: 10.1002/jso.26709] [Reference Citation Analysis]
30 Nara S, Esaki M, Ban D, Takamoto T, Mizui T, Shimada K. Role of adjuvant and neoadjuvant therapy for resectable biliary tract cancer. Expert Rev Gastroenterol Hepatol 2021;15:537-45. [PMID: 33793366 DOI: 10.1080/17474124.2021.1911645] [Reference Citation Analysis]
31 Pan Y, Si H, Jia R, Deng G, Yan H, Fan M, Gou M, Chen S, Zhang N, Shi Y, Qian N, Dai G. Analysis of a Systemic Inflammatory Biomarker in Advanced Bile Tract Carcinoma Treated with Anti-PD-1 Therapy: Prognostic and Predictive Significance of Lung Immune Prognostic Index Score. J Oncol 2022;2022:1427779. [PMID: 35342416 DOI: 10.1155/2022/1427779] [Reference Citation Analysis]
32 Chen R, Zheng D, Li Q, Xu S, Ye C, Jiang Q, Yan F, Jia Y, Zhang X, Ruan J. Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215853] [Reference Citation Analysis]
33 Oneda E, Abu Hilal M, Zaniboni A. Biliary Tract Cancer: Current Medical Treatment Strategies.Cancers (Basel). 2020;12. [PMID: 32423017 DOI: 10.3390/cancers12051237] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
34 Chen Y, Zhang B, Liu C, Cao Y, Lyu C, Qiu M. Clinical efficacy of adjuvant treatments for patients with resected biliary tract cancer: a systematic review and network meta-analysis. BMJ Open 2022;12:e051421. [PMID: 35440445 DOI: 10.1136/bmjopen-2021-051421] [Reference Citation Analysis]
35 Cigliano A, Chen X, Calvisi DF. Current challenges to underpinning the genetic basis for cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2021;15:511-26. [PMID: 33888034 DOI: 10.1080/17474124.2021.1915128] [Reference Citation Analysis]
36 Kendre G, Marhenke S, Lorz G, Becker D, Reineke-Plaaß T, Poth T, Murugesan K, Kühnel F, Woller N, Wirtz RM, Pich A, Marquardt JU, Saborowski M, Vogel A, Saborowski A. The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma. Hepatology 2021;74:1357-70. [PMID: 33709535 DOI: 10.1002/hep.31799] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
37 Wietsma MFT, Molloy C, Bhimani N, de Savornin Lohman EAJ, Gill AJ, Andrici J, Samra J, de Reuver PR, Hugh TJ. Gallbladder carcinoma outcomes in an Australian tertiary referral hospital. ANZ J Surg 2021;91:603-8. [PMID: 33604992 DOI: 10.1111/ans.16663] [Reference Citation Analysis]
38 Fan B, Xu X, Wang X. Mutational landscape of paired primary and synchronous metastatic lymph node in chemotherapy naive gallbladder cancer. Mol Biol Rep 2022;49:1295-301. [PMID: 34988893 DOI: 10.1007/s11033-021-06957-y] [Reference Citation Analysis]
39 Edeline J, Hirano S, Bertaut A, Konishi M, Benabdelghani M, Uesaka K, Watelet J, Ohtsuka M, Hammel P, Kaneoka Y, Joly JP, Yamamoto M, Monard L, Ambo Y, Louvet C, Ando M, Malka D, Nagino M, Phelip JM, Ebata T. Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies. Eur J Cancer 2022;164:80-7. [PMID: 35182925 DOI: 10.1016/j.ejca.2022.01.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]